98%
921
2 minutes
20
Enhancers are noncoding DNA elements that are present upstream or downstream of a gene to control its spatial and temporal expression. Specific histone modifications, such as monomethylation on histone H3 lysine 4 (H3K4me1) and H3K27ac, have been widely used to assign enhancer regions in mammalian genomes. In recent years, emerging evidence suggests that active enhancers are bidirectionally transcribed to produce enhancer RNAs (eRNAs). This finding not only adds a new reliable feature to define enhancers but also raises a fundamental question of how eRNAs function to activate transcription. Although some believe that eRNAs are merely transcriptional byproducts, many studies have demonstrated that eRNAs execute crucial tasks in regulating chromatin conformation and transcription activation. In this review, we summarize the current understanding of eRNAs from their biogenesis, functions, and regulation to their pathological significance. Additionally, we discuss the challenges and possible mechanisms of eRNAs in regulated transcription.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1042/EBC20200014 | DOI Listing |
Genes Dev
September 2025
Department of Biological Sciences, Columbia University, New York, New York 10027, USA;
Enhancer RNAs (eRNAs) are transcribed by during enhancer activation but are typically rapidly degraded in the nucleus. During states of reduced RNA surveillance, however, eRNAs and other similar "noncoding" RNAs (including, e.g.
View Article and Find Full Text PDFActa Pharmacol Sin
September 2025
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Chemotherapeutic resistance is a significant issue in the treatment of breast cancer, which is related to pyroptosis inhibition. Increasing evidence suggests that long non-coding RNAs (lncRNAs) contribute to tumorigenesis and drug resistance. In this study we investigated the role of the lncRNA STMN1P2 in doxorubicin resistance in breast cancer, as well as its correlation with pyroptosis inhibition.
View Article and Find Full Text PDFBiochem Genet
September 2025
Department of Biology, Da.C., Islamic Azad University, Cheshmeh-Ali Boulevard, Sa'dei Square, Damghan, Iran.
Gastric cancer (GC) is one of the leading causes of cancer-related deaths globally. Enhancer of zeste homolog 2 (EZH2), a methyl-transferase and master transcriptional regulator frequently overexpresses in a variety of malignancies. Long non-coding RNAs (lncRNAs) play a significant role in regulating gene expression and are intricately involved in the EZH2 oncogenic regulatory network.
View Article and Find Full Text PDFNaunyn Schmiedebergs Arch Pharmacol
September 2025
Department of Nephrology, Heilongjiang Beidahuang Group General Hospital, Harbin, 150088, China, Heilongjiang.
Long non-coding RNAs (lncRNAs) are distinguished by having a length of over 200 nucleotides and no protein-coding ability. The molecular functions of lncRNAs are diverse and include regulating the activity of small RNAs and proteins, guiding the process of epigenetic alterations, and serving as enhancer RNAs. Moreover, they have a very tissue-specific pattern of expression.
View Article and Find Full Text PDF